ライフサイエンスコーパス: racemate

1 fluralaner (Bravecto, presently sold as the racemate).

2 promote the background reaction to form the racemate.

3 igher than those of S-(-)[2-13C]equol or the racemate.

4 breaking induced by an achiral surface in a racemate.

5 o successive evaporations to precipitate the racemate.

6 attributable to a specific enantiomer in the racemate.

7 stability at room temperature, favoring the racemate.

8 city of its residues relative to that of the racemate.

9 tural product families are reported as their racemates.

10 oselectively resolve 6 additional amino acid racemates.

11 on between those of the conglomerate and the racemates.

12 reater potency than the other three possible racemates.

13 roarrhythmic activity than the corresponding racemates.

14 erences observed between enantiomers and the racemates.

15 butyric acid and norvaline, were found to be racemates.

16 differences in Vss were observed between the racemates.

17 6 were twice as potent as the corresponding racemates.

18 A PLK4 X-ray co-structure with racemate 18 revealed preferential binding of the 1R,2S e

19 Three active racemates (20, 22, 25) were separated into the enantiome

20 Separation of racemate 30 afforded 32, the R enantiomer, which demonst

21 tions of compound 41 (the decanoate ester of racemate 32) eliminated cocaine-maintained behavior for

22 finities of the enantiomers 8 and 12 and the racemate 4 at guinea pig, rat, and cloned human A1- and

23 630 +/- 140 microM) was more potent than the racemate 6 (IC50 = 730 +/- 88 microM) while the R-isomer

24 -methyltetrahydrofolic acid (5-MTHF) and its racemate [6R,S] form was made by TEAC assay at different

25 enoid biosynthesis, is currently marketed as racemate against dicotyledonous weeds in cereals.

26 chiral soil herbicide currently marketed as racemate against dicotyledonous weeds in cereals.

27 erts spontaneously to the former, which is a racemate and showed cell protection against RIPs.

28 The ability of TZF to simultaneously form racemate and solid solution originates from its conforma

29 re more potent than their S counterparts and racemates and (R)-2 was more efficient than (R)-1 and th

30 high affinity for VAChT (Ki = 0.93-18 nM for racemates) and moderate to high selectivity for VAChT ov

31 y in hemoglobin solutions than its antipode, racemate, and RSR13.

32 Fluid phase separations of racemates are difficult because the subtle, short-ranged

33 bias (data available only for systems whose racemates are stable enough to exist) and a possible kin

34 Initial studies with a racemate at 1.85 A resolution failed to identify the chi

35 ed from thalidomide is developed and sold as racemates because of racemization at the chiral center o

36 Potential substitution of the racemate by (-)-beflubutamid should therefore be further

37 or instance, the resolution of some helicene racemates by "hand picking" of a few homochiral single e

38 rowth rate compared to that of the competing racemate (by 4- to 40-fold between 80 and 146 degrees C)

39 Therapeutics developed and sold as racemates can exhibit a limited therapeutic index becaus

40 lative stability of the conglomerate and the racemate changes with the molecule's degree of chirality

41 theses represent a diastereomeric mixture or racemate; compound numbers without parentheses represent

42 rackets represent diastereomeric mixtures or racemates; compound numbers without brackets represent e

43 ally useful stereopromiscuity toward a toxic racemate, concomitant with high catalytic efficiency and

44 tors favor conglomerate crystallization over racemate crystallization.

45 nomalous dispersion (MAD) phasing from quasi-racemate crystals was then used to determine the X-ray s

46 Even as a racemate, DAG-lactone 31 showed low namomolar binding af

47 re rapidly identified, and resolution of the racemate demonstrated that only the R-enantiomer display

48 e excess energy of the conglomerate over the racemate, (E(C) - E(R)), increases with the size of the

49 ide (SR141716) was nearly double that of the racemate for the same determination; therefore, the acti

50 orm had higher antioxidant activity than its racemate form in the TEAC assay at all pHs, with similar

51 ctive formation of a C60 fullerene bisadduct racemate from a complex mixture of 130 bisadducts.

52 All target compounds were synthesized as racemates from 1,3-dihydroxy-2-propanone.

53 ess free energy of the conglomerate over the racemate, (G(C) - G(R)), shows no simple relation with t

54 emical properties of both SubPc-TCBD-aniline racemates have been investigated using a wide range of e

55 linkers seemed to impart antagonism even as racemates; however, the potency of these analogues in th

56 gical activities of both enantiomers and the racemate in field trials showed that the (S)-(+)-enantio

57 iracemate, which is then treated like a true racemate in successive steps of the synthesis.

58 ined the effect of inclusion or exclusion of racemates in the partial least squares (pls) analysis.

59 separation of enantiomers of a wide range of racemates including pharmaceuticals, amino acids, and ca

60 provided the chiral resolution of around 20 racemates, including drugs, illegal drugs, amino-acids,

61 nable the selective permeation of a range of racemates, including mandelic acid (Man), Fmoc-phenylala

62 ing a structural phase transition, while the racemate is mechanically inactive.

63 nough to exist) and a possible kinetic bias (racemates may be easier to crystallize than conglomerate

64 ystallization of achiral precursors yielding racemate metal organic frameworks/coordination polymers

65 s of chiral molecules tend to aggregate into racemate (molecularly heterochiral) crystals much more f

66 pon mixing 26% of (M)-heptahelicene into the racemate monolayer, only the (M)-pentahelicene enantiomo

67 pe fibrinogen receptor antagonist RWJ-50042 (racemate of 1), which was derived from a unique approach

68 icate racemic mixtures; thus (3b+3b') is the racemate of 3b and 3b'), and tripeptide 13 were synthesi

69 enantiopure oxiranylpropargylic ester 13, a racemate of cyclopentenone (R*,S*)-16 was obtained.

70 Additionally, the enantiomers and racemate of each metabolite were assayed for inhibition

71 o pure enantiomers of petrocortyne A and the racemate of its diastereomer.

72 A racemate of two opposite and resolvable enantiomers is g

73 ituted quinolizidines (207I (IV), 233A (V)), racemates of alkaloids found in the skins of neotropical

74 Racemates of five chiral resorcin[4]arenes, four tetra-O

75 Racemates often have lower solubility than enantiopure c

76 Adsorption of a pentahelicene racemate on a Au(111) surface leads to 2D conglomerate c

77 numbers written within brackets represent a racemate or a diastereomeric mixture; compound numbers w

78 hibited greater biological activity than the racemates or (+)-isomers.

79 ves with a stoichiometry of two molecules of racemate per enzyme flavin.

80 Very good separations of model racemate (R,S)-N-3,5-dinitrobenzoylleucine were achieved

81 lta and S-Delta in ClCH2CH2Cl are mixed, the racemate rac-Delta forms an organogel that is composed o

82 usually crystallizes as a racemic compound (racemate), rarely as a conglomerate, and even more rarel

83 ates a tendency for chiral molecules to form racemates rather than conglomerates.

84 oselectivity toward primary amine-containing racemates, separating 98% of those tested.

85 This is the first example of a protein racemate that crystallized in space group I41/a.

86 e-bridged phenylmorphans, all but two of the racemates, the ortho- and para-b-oxide-bridged phenylmor

87 prepared by resolution of the corresponding racemates, using the lipase formulation Novozyme 435.

88 A 3R,4R,5R/3S,4S,5S racemate was found to have greater potency than the othe

89 crystallized, and the structure of the true racemate was solved at a resolution of 2.7-2.15 A.

90 separation of dihydropyrimidinone (DHP) acid racemate was studied for the first time by quasi-equilib

91 solution of cationic (77%) and neutral (85%) racemates was very high.

92 The best model was obtained when racemates were excluded from QSAR analysis.

93 The most potent H4R agonists among 14 racemates were separated by chiral HPLC, yielding eight

94 e compounds, which have been all isolated as racemates, were unambiguously characterized by (1)H and

95 icient to predict whether the multimolecular racemate will or will not segregate.

96 optical purity by optical resolution of the racemate with the camphoric acids.